In HNSCC, a phase I trial (NCT02517398) of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, revealed outcomes equivalent to those of pembrolizumab and nivolumab treatments. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.